Supernus Projects Strong 2026 Growth
Supernus Pharmaceuticals has outlined ambitious revenue guidance for 2026, projecting between $840 million and $870 million as the company accelerates its commercial strategy. During the Q1 earnings call, management highlighted significant momentum for ONAPGO, with a second-supplier FDA filing targeted for Q3, a move that could strengthen market position and supply chain resilience. The company's portfolio growth is being driven by strong performance from Qelbree and ZURZUVAE, which continue to gain market traction. Supernus reiterated its full-year guidance while navigating regulatory timelines and associated risks. The second-supplier designation for ONAPGO represents a critical milestone that could enhance competitive positioning and reduce supply vulnerabilities.
MA
Wednesday, May 6, 2026 at 10:40 AM
0
0
1
3